PURPOSE: There are limited data in the literature on the probability of dry-eye complications according to radiotherapy dose. This study investigates the risk of radiation-induced severe dry-eye syndrome in patients in whom an entire orbit was exposed to fractionated external beam irradiation. METHODS AND MATERIALS: Between October 1964 and May 1989, 33 patients with extracranial head and neck tumors received irradiation of an entire orbit. Most patients were treated with 60Co. The dose to the lacrimal apparatus was calculated at a depth of 1 cm from the anterior skin surface, the approximate depth of the major lacrimal gland. The end point of the study was severe dry-eye syndrome sufficient to produce visual loss secondary to corneal opacification, ulceration, or vascularization. RESULTS: Twenty patients developed severe dry-eye syndrome. All 17 patients who received doses > or = 57 Gy developed severe dry-eye syndrome. Three (19%) of 16 patients who received doses < or = 45 Gy developed severe dry-eye syndrome; injuries in the latter group were much slower to develop (4 to 11 years) than in the higher dose group, in whom corneal vascularization and opacification were usually pronounced within 9-10 months. There were no data for the range of doses between 45.01 and 56.99 Gy. The data did not suggest an increased risk of severe dry-eye syndrome with increasing age. CONCLUSION: Data from the current series and the literature are combined to construct a sigmoid dose response curve. The incidence of injury increases from 0% reported after doses < or = 30 Gy to 100% after doses > or = 57 Gy.
PURPOSE: There are limited data in the literature on the probability of dry-eye complications according to radiotherapy dose. This study investigates the risk of radiation-induced severe dry-eye syndrome in patients in whom an entire orbit was exposed to fractionated external beam irradiation. METHODS AND MATERIALS: Between October 1964 and May 1989, 33 patients with extracranial head and neck tumors received irradiation of an entire orbit. Most patients were treated with 60Co. The dose to the lacrimal apparatus was calculated at a depth of 1 cm from the anterior skin surface, the approximate depth of the major lacrimal gland. The end point of the study was severe dry-eye syndrome sufficient to produce visual loss secondary to corneal opacification, ulceration, or vascularization. RESULTS: Twenty patients developed severe dry-eye syndrome. All 17 patients who received doses > or = 57 Gy developed severe dry-eye syndrome. Three (19%) of 16 patients who received doses < or = 45 Gy developed severe dry-eye syndrome; injuries in the latter group were much slower to develop (4 to 11 years) than in the higher dose group, in whom corneal vascularization and opacification were usually pronounced within 9-10 months. There were no data for the range of doses between 45.01 and 56.99 Gy. The data did not suggest an increased risk of severe dry-eye syndrome with increasing age. CONCLUSION: Data from the current series and the literature are combined to construct a sigmoid dose response curve. The incidence of injury increases from 0% reported after doses < or = 30 Gy to 100% after doses > or = 57 Gy.
Authors: Jessica A Lawrence; Lisa J Forrest; Michelle M Turek; Paul E Miller; T Rockwell Mackie; Hazim A Jaradat; David M Vail; Richard R Dubielzig; Richard Chappell; Minesh P Mehta Journal: Vet Radiol Ultrasound Date: 2010 Sep-Oct Impact factor: 1.363
Authors: Sara Abu-Ghanem; Ran Ben-Cnaan; Igal Leibovitch; Gilad Horowitz; Gadi Fishman; Dan M Fliss; Avraham Abergel Journal: Eur Arch Otorhinolaryngol Date: 2013-09-20 Impact factor: 2.503
Authors: Kimberly F Whelan; Kayla Stratton; Toana Kawashima; John W Waterbor; Robert P Castleberry; Marilyn Stovall; Charles A Sklar; Roger J Packer; Pauline Mitby; Candice L Aitken; Julie Blatt; Leslie L Robison; Ann C Mertens Journal: Pediatr Blood Cancer Date: 2010-01 Impact factor: 3.167
Authors: Alberto Mejía-Novelo; Alberto Alvarado-Miranda; Flavia Morales-Vázquez; Carlos Gamboa-Vignole; Rodrigo Núñez-Gómez; Noel Castañeda-Soto; Alfonso Dueñas-González; Myrna Candelaria-Hernández; Fernando Lara-Medina Journal: Med Oncol Date: 2004 Impact factor: 3.064
Authors: Eduardo M Rocha; Ana P Cotrim; Changyu Zheng; Paola Perez Riveros; Bruce J Baum; John A Chiorini Journal: Hum Gene Ther Date: 2013-04 Impact factor: 5.695
Authors: S S Batth; R Sreeraman; E Dienes; L A Beckett; M E Daly; J Cui; M Mathai; J A Purdy; A M Chen Journal: Br J Radiol Date: 2013-10-28 Impact factor: 3.039